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Abstract
Background: While hypertension is a leading risk factor for an initial stroke, the role of blood
pressure lowering to prevent subsequent stroke is less clear. The results of recent large clinical
trials investigating effects of antihypertensive agents in patients with a history of stroke have not
shown a significant benefit; findings that are at odds with previous data. Our meta-analysis
systematically evaluates the available, relevant trials to examine the role of antihypertensive drugs
in preventing recurrent stroke.
Methods:  MEDLINE, CENTRAL, and ClinicalTrials.gov were systematically searched and
bibliographies from key reports were examined. All randomized, placebo-controlled trials that
tested blood pressure lowering agents in patients with stroke or transient ischemic attack were
identified. The results from these trials were combined and meta-analyses were performed.
Results: Ten studies were found to contain relevant endpoints and presented data allowing meta-
analysis. Agents that lowered blood pressure reduced recurrent stroke (OR 0.71, 95% CI 0.59-
0.86, P = 0.0004) and cardiovascular events (OR 0.69, 95% CI 0.57-0.85, P = 0.0004) in patients
with a previous stroke or TIA. These agents did not affect the rate of myocardial infarction (OR
0.86, 95% CI 0.73-1.01, P = 0.07) or all-cause mortality (OR 0.95, 95% CI 0.83-1.07, P = 0.39) in
this patient population.
Conclusion:  Despite recent large trials showing no significant effect, in patients that have
experienced a TIA or stroke, blood pressure lowering agents reduced the occurrence of
subsequent stroke and cardiovascular events. The rate of myocardial infarction and all-cause
mortality was unchanged.
Background
Hypertension is the leading risk factor for cerebrovascular
accident [1] and increases the risk of stroke sevenfold [2].
While primary prevention of stroke must include ade-
quate blood pressure (BP) control, BP control in the sec-
ondary prevention of stroke is less clear. Individuals who
suffer a stroke or transient ischemic attack (TIA) are at
increased risk for another cardiovascular event [3]. While
lowering BP during an acute cerebrovascular accident
remains controversial, there may be a benefit to lowering
blood pressure after the acute phase of the event has
passed. Meta-analyses indicate that BP reduction can
decrease the risk of recurrent stroke by one third [4]. In
primary stroke prevention, BP is strongly associated with
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stroke risk and association is continuous down to pres-
sures of 115/75 mmHg [5]. In secondary stroke preven-
tion, there has been concern that too great a BP reduction
can interfere with cerebral blood flow and can lead to
ischemia. In fact, earlier cohort studies seemed to show a
J-shaped curve of blood pressure and stroke recurrence
[6,7]. However, recent studies such as HOPE [8,9] and
PROGRESS [10,11] have failed to demonstrate this nega-
tive association at lower BP.
Rashid and coauthors performed a systematic review of
blood pressure and recurrent stroke in 2003 [12] and con-
cluded that for patients with previous stroke or TIA,
blood-pressure lowering agents reduced the risk of subse-
quent cardiovascular events. Furthermore, the authors
report that blood pressure reduction is negatively associ-
ated with recurrent stroke and myocardial infarction.
Since 2003 however, results from large randomized con-
trolled trials have appeared to contradict this finding, spe-
cifically the recent study using the angiotensin receptor
blocker telmisartan [13] and the interpretation of the
PROGRESS trial [14]. Our current investigation provides
an updated systematic review of the literature with meta-
analysis examining the role of BP reduction and the use of
antihypertensive agents to prevent the recurrence of
stroke.
Methods
Identification, Inclusion and Exclusion
Clinical trials were identified using MEDLINE/PubMed
and CENTRAL (Cochrane Central Register of Controlled
Trials) in April 2009. Literature searches were performed
using the following search terms: "recurrence" OR "recur-
rent" OR "secondary prevention" AND "stroke." These
search terms resulted in 7,046 primary articles from the
PubMed database, including 1,702 review articles (see
Figure 1 for a flow diagram). To these terms were added
either "blood pressure" or "antihypertensive" which
reduced the number of entries to 606 and 345 articles
respectively. When these results were limited to clinical
trials, meta-analysis and randomized controlled trials, the
number of articles decreased to 119 for "blood pressure"
and 51 for "antihypertensive." The resulting articles were
then manually screened and duplicates removed. To
account for the possibility that the PubMed search
excluded one or more useful studies, the authors surveyed
the bibliographies of relevant articles and reviews for
additional articles that were not returned in the database
search. Also, the same search terms were used in the Clin-
icalTrials.gov search engine to identify registered clinical
trials that are complete, ongoing and currently enrolling
participants.
Articles were excluded if at least one treatment group or
study arm was not comprised entirely of patients with a
previous stroke and/or TIA. Similarly, clinical trials were
excluded if they were not compared against a randomized
placebo group. In certain cases, BP was presented as part
of an integrated approach to secondary stroke prevention
and these articles were excluded from our analysis. Clini-
cal trials that studied the effects of blood pressure lower-
ing agents during acute stroke were also excluded. [See
Additional file 1 for a quality of reporting of meta-analy-
ses (QUOROM) statement checklist.]
Data Abstraction
Data were extracted independently by the authors and any
disagreements were resolved by consensus.
Clinical Outcomes
The clinical trials surveyed in this meta-analysis reported
various primary, secondary and tertiary endpoints. The
endpoints of interest for our analysis were stroke recur-
rence, cardiovascular event, myocardial infarction and all-
cause mortality. The stroke recurrence endpoint included
both fatal and non-fatal stroke. For the purposes of this
analysis, the term "stroke" included both ischemic stroke
and intracerebral hemorrhage, although these subgroups
are identified in the text when possible. The myocardial
infarction endpoint included fatal and non-fatal events
unless otherwise noted. Cardiovascular event, the end-
point used in the HOPE [8] and PRoFESS trials [13],
includes death from a cardiovascular cause, recurrent
stroke or myocardial infarction.
Statistical Analysis
Individual data including the number of participants
experiencing a clinical outcome and the total number of
study participants for each arm were extracted to deter-
mine odds ratios for each study or subgroup. These data
were analyzed using Review Manager (RevMan) version
5.0 [15]. The Mantel-Haenszel method was used for all
odds ratio analyses and all data were dichotomous. We
assumed that significant statistical heterogeneity existed
among the trials studies given their low number and the
large differences between studies. A random effects model
was used for all analyses. Inconsistency was determined
by chi-square testing and determination of the I2 statistic
[16]. Putative heterogeneity was identified by I2 values
above 40% and a significant Chi square statistic of P < 0.1.
Where significant heterogeneity existed, a random effects
model was used and we attempted to identify sources of
heterogeneity. Funnel plots were constructed [17] to iden-
tify publication bias among studies. Ninety-five percent
confidence intervals were used throughout and P values
less than 0.05 were considered statistically significant.
Results
Ten randomized clinical trials were identified as having
study participants with prior TIA, stroke or "reversibleInternational Archives of Medicine 2009, 2:30 http://www.intarchmed.com/content/2/1/30
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Flow diagram of included studies Figure 1
Flow diagram of included studies.International Archives of Medicine 2009, 2:30 http://www.intarchmed.com/content/2/1/30
Page 4 of 8
(page number not for citation purposes)
ischemic neurologic defect" who were chronically treated
with a blood pressure lowering agent [8,10,13,18-24]. The
summary of included trials is shown in Table 1. Some
analyses did not include all ten trials because the clinical
endpoint could not be clearly elucidated from the text
[25-32]. Excluded trials are listed in Table 2.
All ten studies reported stroke recurrence as a primary or
secondary endpoint. The total number of patients
included in this analysis was 37,737 of which 18,903
received active treatment, 18,740 received placebo, and 94
received nothing. The Martí Massó study [19] was the only
open trial included in the analysis. Lowering blood pres-
sure significantly decreased the odds ratio of stroke recur-
rence shown in Additional file 2 (OR 0.71, 95% CI 0.59-
0.86, P = 0.0004). Tests [16] showed that the ten studies
analyzed had a considerable degree of heterogeneity (P <
0.01, I2 = 78%). Along the ten studies there were varia-
tions in study population. These variations included age,
race, time of follow-up, antihypertensive medication used
and degree of hypertension at trial start. Only one study,
BPLPRS [23], lead to significant funnel plot asymmetry
Table 1: Characteristics of randomized clinical trials investigating the role of blood pressure lowering on stroke recurrence.
Study Year Drug Type of Stroke Subjects 
(Treated, 
Control)
Mean Follow-up 
Period (years)
Decrease in BP 
with Treatment 
(sys/dia in mmHg)
BPLPRS [23] 2005 Perindopril + 
indapamide vs. 
placebo
TIA, Isch, Hem 1520 (762, 758) 4 14/6
Dutch TIA [20] 1993 Atenolol vs. placebo TIA or non-disabling 
Isch
1473 (732, 741) 2.6 5.8/2.9
HOPE [33] 2000 Ramipril vs. placebo TIA or stroke NS 1013 (500, 513) 5 NS
HSCSG [18] 1974 Deserpidine + 
methyclothiazide vs. 
placebo
TIA, Isch, Hem 452 (233, 219) 2.8 25/12.3
Martí Massó [19] 1990 Nicardipine vs. 
nothing
TIA, RIND, Isch 264 (170, 94) 1 NS
PATS [21] 1995 Indapamide vs. 
placebo
TIA, Isch, Hem 5665 (2841, 2824) 2.8 6.2/2.9
PRoFESS [13] 2008 Telmisartan vs. 
placebo
Isch 20332 
(10146, 10186)
2.5 3.8/2
PROGRESS [10] 2001 Perindopril + 
indapamide OR 
perindopril vs. 
placebo
TIA, Isch, Hem 6105 (3051, 3054) 4 9/4
Perindopril vs. 
placebo
2561a (1281, 1280) 5/3
Perindopril + 
indapamide vs. 
placebo
3544a (1770, 1774) 12/5
SCOPE [24] 2005 Candesartan vs. 
placebo
NS 193 (96, 97) 3.7 -0.4/1.5b
TEST [22] 1995 Atenolol vs. placebo NS 720 (372, 348) 2.5 4/3
Hem, hemorrhagic stroke or intracerebral hemorrhage; Isch, ischemic stroke; NS, not specified in published report; RIND, reversible ischemic 
neurological defect; TIA, transient ischemic attack.
a Part of the original 6,105 PROGRESS study participants.
b Mean systolic blood pressure increased in treatment group.International Archives of Medicine 2009, 2:30 http://www.intarchmed.com/content/2/1/30
Page 5 of 8
(page number not for citation purposes)
(Figure 2). When this study was eliminated from the anal-
ysis, the blood pressure lowering was still associated with
a reduced risk of recurrent stroke though the effect was less
pronounced (OR 0.77, 95% CI 0.66-0.90, P = 0.0009).
BPLPRS studied the effect of ACE inhibitor, perindopril,
combined with a diuretic, indapamide, on recurrent
stroke in Chinese patients exclusively.
Cardiovascular event is a composite endpoint which
included death from any vascular cause, non-fatal stroke
and non-fatal myocardial infarction. This composite was
used in the HOPE trial [33] and has been adopted by
authors in subsequent trials [13]. Random effects analysis
[see Additional file 3] showed that regardless of the agent
used, blood pressure reduction reduced the number of
cardiovascular events (OR 0.69, 95% CI 0.57-0.85, P =
0.0004). The Martí Massó study [19] was not used in the
meta-analysis because the cardiovascular event endpoint
could not be determined from the published report. The
number of subjects was 18,733 for treated groups and
18,740 for placebo. Heterogeneity was again quite high
and likely due to different antihypertensive medications
used among the studies.
The relative risks of myocardial infarction and all-cause
mortality were determined from eight and seven of the ten
trials, respectively. The SCOPE [24] and Martí Massó [19]
studies were omitted from the myocardial infarction anal-
ysis and the HOPE [8], PATS [21] and SCOPE [24] studies
were omitted from the all-cause mortality analysis
because data regarding the respective endpoint could not
be obtained. Despite these omissions each analysis
included over 15,000 patients. There were 18,637 patients
in the treatment arm and 18,638 patients in the placebo
arm for the myocardial infarction endpoint and 15,466 in
the treated arm and 15,400 in the placebo arm for all-
cause mortality. Tests of heterogeneity and inconsistency
were relatively low for both analyses (Myocardial infarc-
tion, P = 0.24, I2 = 24%; All-cause mortality, P = 0.21, I2 =
29%). As shown in Additional file 4, blood pressure low-
ering agents did not show a statistically significant effect
on myocardial infarction in patients that had experienced
a stroke or TIA (OR 0.86, 95% CI 0.73-1.01, P = 0.07). The
all-cause mortality rate was similar between both active
and placebo treated patients (OR 0.95, 95% CI 0.83-1.07,
P = 0.39). Additional file 5 shows the forest plot of studies
that included explicit all-cause mortality data.
Discussion
Results from recent large randomized clinical trials [13]
have called into question the role of blood pressure low-
ering agents in patients with previous stroke. Stroke survi-
vors usually have significant pill burdens [34] making
judicious medication selection an important part of the
health care plan. The number of randomized, prospective
studies that specifically examine the role of blood pressure
control in patients that have already experienced a stroke
or TIA is relatively low [35]. The results of systematic
review and meta-analysis show that blood pressure lower-
ing medications confer significant benefit to stroke and
TIA survivors by reducing the rate of subsequent strokes
and major cardiovascular events. This is especially impor-
tant given that between 8 and 15 percent of stroke survi-
vors will experience a second event within the first year
[36] and the recurrent events lead more often to disability
and death [37].
The findings of our analysis are in line with a previous
meta-analysis of the subject done by Rashid and Bath in
2003 [12]. They found that all cases of recurrent stroke
and non-fatal stroke were fewer in the antihypertensive
treated group. In contrast to the Rashid meta-analysis,
Table 2: Selected trials identified by literature search and reasons for exclusion.
Study Reason for Exclusion
ACCESS [27] Acute study, no control
Kaplan [31] Observational, not randomized or interventional
Lehigh Valley [26] Not randomized or interventional
MOSES [30] Not placebo controlled, compared two antihypertensives
Ribas Mundó [25] Not randomized or placebo controlled
PEACE [28] Less than ten stroke survivors per arm
SAPSI [29] Not randomized or interventional
VALUE [32] Not placebo controlled, compared two antihypertensivesInternational Archives of Medicine 2009, 2:30 http://www.intarchmed.com/content/2/1/30
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blood pressure lowering agents in patients that had had a
previous stroke did not alter the rate of subsequent myo-
cardial infarction in our analysis. This finding is likely due
to the results of the PRoFESS trial [13] which were not
available in 2003. The PRoFESS trial reports essentially
identical rates of myocardial infarction in both the treat-
ment and placebo groups. Because of the size of the trial,
it was given the largest share of relative weight (28.3%) of
the studies we analyzed [see Additional file 4]. When this
trial was omitted from our current analysis, pharmacolog-
ical blood pressure treatment conferred a statistically sig-
nificant benefit for myocardial infarction; however there
is no reason to omit the participants of this large, high-
quality study. Thus in patients that have experienced a
stroke or TIA, blood pressure reduction is not a major
determinant of myocardial infarction risk. However, the
overall cardiovascular health of stroke patients should not
be neglected.
As shown in our analysis, blood pressure reduction in this
patient population does not reduce all-cause mortality. It
does, however, reduce cardiovascular events, and mortal-
ity from vascular causes is part of the composite endpoint.
Information regarding cardiovascular mortality was only
available for four out of the ten relevant trials and did not
yield useful analysis.
The TRANSCEND trial [38] is notably missing from this
meta-analysis. While not the primary focus, the TRAN-
SCEND trial included a subset of 1,302 patients with pre-
vious ischemic stroke of which 648 and 654 were
randomized to telmisartan and placebo groups, respec-
tively. The number of relevant endpoints could not be
obtained as the data is still being compiled for a forth-
coming report. Nevertheless, results from the TRAN-
SCEND study are expected to be similar to the larger
PRoFESS trial in which telmisartan was also the antihyper-
tensive.
Funnel plot comparison of studies examining the effect of blood pressure lowering agents on the risk of recurrent stroke Figure 2
Funnel plot comparison of studies examining the effect of blood pressure lowering agents on the risk of recur-
rent stroke. One study, BPLPRS, fell outside of the 95% confidence region.International Archives of Medicine 2009, 2:30 http://www.intarchmed.com/content/2/1/30
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There are always limitations to using data across trials, as
opposed to data regarding individual patients. Indeed our
meta-analysis does indicate inconsistencies in the data
that extend beyond statistical heterogeneity, especially in
the recurrent stroke and cardiovascular event groups.
Some of this heterogeneity may be resolved if individual
agents or drug classes were considered individually.
Unfortunately due to the limited number of studies, gen-
eralizations about specific drug classes could be mislead-
ing. Studies that were excluded from our analysis because
they did not include a control group could shed some
light on this issue. For example, the MOSES trial [30]
compared the angiotensin II receptor blocker (ARB)
against the calcium channel blocker nitrendipine in
patients with a history of a cerebral event. The ARB con-
ferred enhanced benefit for the combined endpoint of car-
diovascular events [30]. An important caveat regarding
the MOSES trial is that a large portion of trial participants
in both trial arms were on various blood pressure agents
concomitantly.
Blood pressure control remains an important considera-
tion for patients who have experienced previous TIA or
stroke. Given the available data, blood pressure control
does confer a benefit to stroke survivors by reducing risk
of recurrent stroke and cardiovascular events. Optimal
subacute and chronic treatment following stroke should
be individualized to patient's needs but should include at
least one blood pressure lowering agent.
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